Xenetic Biosciences, Inc. (XBIO) Form 8-K — Sep 16, 2026
Xenetic Biosciences has signed a definitive Share Exchange Agreement dated September 14, 2026 to acquire the entire issued share capital of Santersus AG, a Swiss corporation, in a transaction intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, with Santersus becoming a wholly owned subsidiary of Xenetic. The deal is effectively a reverse merger: holders of Santersus shares are expected to own approximately 85% of the combined company on a fully diluted basis, leaving existing Xenetic stockholders with the balance.
Key figures
- New ticker
- SNTS
- Tax treatment
- Intended tax-free reorganization under IRC Section 368(a)
- Agreement date
- 2026-09-14
- New company name
- Santersus Bio, Inc.
- Lockup period days
- 180
- Termination fee usd
- 500000
- Deal announcement date
- 2026-09-16
- Expense reimbursement cap usd
- 300000
- Post closing board composition
- 8 members: 2 designated by Xenetic, 6 by Santersus; chairman designated by Santersus
- Voting agreement stake percent
- approximately 9.0% of outstanding shares
- Santersus option plan reserve shares
- 600000
- Post closing xenetic holder ownership
- approximately 15% (balance)
- Santersus ordinary shares outstanding
- 2164490
- Santersus preferred shares outstanding
- 455679
- Post closing santersus holder ownership
- approximately 85% (fully diluted, assuming Net Cash of $0 at Closing)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.